Nebenwirkungen · CoAprovel
CoAprovel 300 mg/25 mg film-coated tablets. · Abschnitt 4.8 · PDF-Seite 76
HOS-089506 · Präparat HOS-083831
Table 1: Adverse Reactions in Placebo-Controlled Trials and Spontaneous Reports Investigations: Common: increases in blood urea nitrogen (BUN), creatinine and creatine kinase Uncommon: decreases in serum potassium and sodium Cardiac disorders: Uncommon: syncope, hypotension, tachycardia, oedema Nervous system disorders: Common: dizziness Uncommon: orthostatic dizziness Not known: headache Ear and labyrinth disorders: Not known: tinnitus Respiratory, thoracic and Not known: cough mediastinal disorders: Gastrointestinal disorders: Common: nausea/vomiting Uncommon: diarrhoea Not known: dyspepsia, dysgeusia Renal and urinary disorders: Common: abnormal urination Not known: impaired renal function including isolated cases of renal failure in patients at risk (see section 4.4) Musculoskeletal and connective Uncommon: swelling extremity tissue disorders: Not known: arthralgia, myalgia Metabolism and nutrition Not known: hyperkalaemia disorders: Vascular disorders: Uncommon: flushing General disorders and Common: fatigue administration site conditions: Immune system disorders: Not known: cases of hypersensitivity reactions such as angioedema, rash, urticaria Hepatobiliary disorders: Uncommon: jaundice Not known: hepatitis, abnormal liver function Reproductive system and breast Uncommon: sexual dysfunction, libido changes disorders:
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T17:00:00Z · SHA-256 663294994546958f142b58235345414fc155e758fcd620182b00e348e98154c3 · Passage 13a93497ca04608754d4addfec5eea73893a4574fce51fffc5c83768c0251496 · Zeichen 1033–3209 im Abschnitt